Imiquimod: A topically applied link between innate and acquired immunity

Archives of Dermatology

Volumn 139, Issue 10, 2003, Pages 1347-1350

  Hurwitz, Daniel J ^a   Pincus, Laura ^a   Kupper, Thomas S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; TOLL LIKE RECEPTOR;

BOWEN DISEASE; CYTOKINE RELEASE; HUMAN; IMMUNITY; IMMUNOMODULATION; MALIGNANT LENTIGO; NOTE; PAGET SKIN DISEASE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; SKIN NEOPLASMS;

EID: 0141995600     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.10.1347     Document Type: Note

References (45)

1. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25-30.
2. Schwab R, Elston D. Topical imiquimod for recalcitrant facial flat warts. Cutis. 2000;65:160-163.
3. Hengge U, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contaglosum. Br J Dermatol. 2000;143:1026-1031.
4. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:462-470.
5. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-845.
6. Zampogna J, Flowers F, Roth W, Hassenein A. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol. 2002;47:S229-S235.
7. Suchin K, Junkins-Hopkins J, Rook A. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol. 2002;138:1137-1139.
8. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498-1502.
9. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinomas: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-813.
10. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139:1325-1332.
11. Reiter M, Testerman T, Miller R, Weeks C, Tomal M. Cytokine induction in mice by the immunomodulator imiquimod. J Leukocyte Biol. 1994;55:234-240.
12. Weeks C, Gibson S. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res. 1994;14:81-85.
13. Testerman T, Gerster J, Imbertson L, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukocyte Biol. 1995;58:365-372.
14. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.
15. Imbertson L, Beaurline J, Couture A, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110:734-739.
16. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann J. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973-983.
17. Medzhitov R, Preston-Hurlburt P, Janeway C. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397.
18. Ito T, Amakawa R, Kalsho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002;195:1507-1512.
19. Hemmi H, Kalsho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
20. Gay N, Keith F. Drosophila Toll and IL-1 receptor. Nature. 1991;351:355-356.
21. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 Is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253-258.
22. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol. 2000;2:346-351.
23. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J-I, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature. 1999;398:252-256.
24. Kopp E, Medzhitov R, Carothers J, et al. ECSIT is an evolutionarily conserved intermediate in the Toll/ IL-1 signal transduction pathway. Genes Dev. 1999;13:2059-2071.
25. Xia Y, Makris C, Su B, et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A. 2000;97:5243-5248.
26. Nakano H, Shindo M, Sakon S, et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 1998;95:3537-3542.
27. Israel A. The IKK complex: an integrator of all signals that activate NF-κB? Trends Cell Biol 2000;10:129-133.
28. Yamaoka S, Courtois G, Bessia C, et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell. 1998;93:1231-1240.
29. Wang W, Zhou G, Hu M, Yao Z, Tan T-H. Activation of the hematopoetic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β, (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF-β signal transduction. J Biol Chem. 1997;272:22771-22775.
30. Moriguchi T, Kuroyanagi N, Yamaguchi K, et al. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem. 1996;271:13675-13679.
31. Raingeaud J, Whitmarsh A, Barrett T, Derijard B, Davis R. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol. 1996;16:1247-1255.
32. Re F, Strominger J. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem. 2001;276:37692-37699.
33. Arrighi J-F, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers. J Immunol. 2001;166:3837-3845.
34. Yamamoto M, Sato S, Mori K, et al. A novel Toll/ IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol. 2002;169:6668-6672.
35. Takeda K, Kalsho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
36. Murphy JE, Robert C, Kupper T. Interleukin 1 and cutaneous inflammation: a crucial link between innate and acquired Immunity. J Invest Dermatol. 2000;114:602-608.
37. Hoshino K, Takeuchi O, Kawal T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J Immunol. 1999;162:3749-3752.
38. Jones B, Means T, Heldwein K, et al. Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol. 2001;69:1036-1044.
39. Jurk M, Hell F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002;3:499.
40. Chaung TH, Ulevitch R. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 2000;11:372-378.
41. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531-4537.
42. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun. 2001;2:349-355.
43. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001;31:3388-3393.
44. Wollengerg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119:1096-1102.
45. Gibson S, Lindh J, Riter T, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74-86.